DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Coreg CR (Carvedilol Phosphate) - Indications and Dosage

 


Nutrilib.com
A comprihensive source of nutritional information

INDICATIONS AND USAGE

Heart Failure

COREG CR is indicated for the treatment of mild-to-severe heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitor, and digitalis, to increase survival and, also, to reduce the risk of hospitalization (see CLINICAL TRIALS).

Left Ventricular Dysfunction Following Myocardial Infarction

COREG CR is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) (see CLINICAL TRIALS).

Hypertension

COREG CR is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics (see PRECAUTIONS, Drug Interactions).

DOSAGE AND ADMINISTRATION

General

COREG CR should be taken once daily in the morning with food. COREG CR should be swallowed as a whole capsule. COREG CR and/or its contents should not be crushed, chewed, or taken in divided doses.

Alternative Administration

The capsules may be carefully opened and the beads sprinkled over a spoonful of applesauce. The applesauce should not be warm because it could affect the modified-release properties of this formulation. The mixture of drug and applesauce should be consumed immediately in its entirety. The drug and applesauce mixture should not be stored for future use. Absorption of the beads sprinkled on other foods has not been tested.

Heart Failure

DOSAGE MUST BE INDIVIDUALIZED AND CLOSELY MONITORED BY A PHYSICIAN DURING UP-TITRATION. Prior to initiation of COREG CR, it is recommended that fluid retention be minimized. The recommended starting dose of COREG CR is 10 mg once daily for 2 weeks. Patients who tolerate a dose of 10 mg once daily may have their dose increased to 20, 40, and 80 mg over successive intervals of at least 2 weeks. Patients should be maintained on lower doses if higher doses are not tolerated.

Patients should be advised that initiation of treatment and (to a lesser extent) dosage increases may be associated with transient symptoms of dizziness or lightheadedness (and rarely syncope) within the first hour after dosing. Thus during these periods they should avoid situations such as driving or hazardous tasks, where symptoms could result in injury. In addition, COREG CR should be taken with food to slow the rate of absorption. Vasodilatory symptoms often do not require treatment, but it may be useful to separate the time of dosing of COREG CR from that of the ACE inhibitor or to reduce temporarily the dose of the ACE inhibitor. The dose of COREG CR should not be increased until symptoms of worsening heart failure or vasodilation have been stabilized.

Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics.

The dose of COREG CR should be reduced if patients experience bradycardia (heart rate <55 beats/minute).

Episodes of dizziness or fluid retention during initiation of COREG CR can generally be managed without discontinuation of treatment and do not preclude subsequent successful titration of, or a favorable response to, COREG CR.

Left Ventricular Dysfunction Following Myocardial Infarction

DOSAGE MUST BE INDIVIDUALIZED AND MONITORED DURING UP-TITRATION. Treatment with COREG CR may be started as an inpatient or outpatient and should be started after the patient is hemodynamically stable and fluid retention has been minimized. It is recommended that COREG CR be started at 20 mg once daily and increased after 3 to 10 days, based on tolerability to 40 mg once daily, then again to the target dose of 80 mg once daily. A lower startingdose may be used (10 mg once daily) and/or, the rate of up titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention).Patients should be maintained on lower doses if higher doses are not tolerated. The recommended dosing regimen need not be altered in patients who received treatment with an IV or oral β-blocker during the acute phase of the myocardial infarction.

Hypertension

DOSAGE MUST BE INDIVIDUALIZED. The recommended starting dose of COREG CR is 20 mg once daily. If this dose is tolerated, using standing systolic pressure measured about 1 hour after dosing as a guide, the dose should be maintained for 7 to 14 days, and then increased to 40 mg once daily if needed, based on trough blood pressure, again using standing systolic pressure one hour after dosing as a guide for tolerance. This dose should also be maintained for 7 to 14 days and can then be adjusted upward to 80 mg once daily if tolerated and needed. Although not specifically studied, it is anticipated the full antihypertensive effect of COREG CR would be seen within 7 to 14 days as had been demonstrated with conventional carvedilol tablets. Total daily dose should not exceed 80 mg.

Addition of a diuretic to COREG CR, or COREG CR to a diuretic can be expected to produce additive effects and exaggerate the orthostatic component of COREG CR action.

Use in Patients with Hepatic Impairment

COREG CR should not be given to patients with severe hepatic impairment (see CONTRAINDICATIONS).

HOW SUPPLIED

Capsules: The hard gelatin capsules are filled with white to off-white microparticles and are available in the following strengths:

10 mg − white and green capsule shell printed with GSK COREG CR and 10 mg

20 mg − white and yellow capsule shell printed with GSK COREG CR and 20 mg

40 mg − yellow and green capsule shell printed with GSK COREG CR and 40 mg

80 mg − white capsule shell printed with GSK COREG CR and 80 mg

10 mg 30’s: NDC 0007-3370-13

10 mg 90’s: NDC 0007-3370-59

20 mg 30’s: NDC 0007-3371-13

20 mg 90’s: NDC 0007-3371-59

40 mg 30’s: NDC 0007-3372-13

40 mg 90’s: NDC 0007-3372-59

80 mg 30’s: NDC 0007-3373-13

80 mg 90’s: NDC 0007-3373-59

STORAGE

Store at 25°C (77°F); excursions 15° to 30°C (59° to 86°F). Dispense in a tight, light-resistant container.

COREG CR is a trademark of GlaxoSmithKline.

GlaxoSmithKline

Research Triangle Park, NC 27709

©2007 GlaxoSmithKline. All rights reserved.

March, 2007 CR:L3

Page last updated: 2007-04-23

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008